1. Jagged 2 silencing inhibits motility and invasiveness of colorectal cancer cell lines
- Author
-
Amanda Kit Ching Chan, Sze Chuen Cesar Wong, Brigette B.Y. Ma, Wing Shan Ho, Anthony T.C. Chan, Thomas Chi Chuen Au, Charles Ming Lok Chan, Wan He, and Andrew Sai Kit Chan
- Subjects
0301 basic medicine ,Oncology ,JAG2 ,Cancer Research ,medicine.medical_specialty ,Cell ,Notch signaling pathway ,Biology ,03 medical and health sciences ,0302 clinical medicine ,stomatognathic system ,Internal medicine ,medicine ,Gene silencing ,neoplasms ,Oncogene ,Cell growth ,Cancer ,Articles ,Cell cycle ,medicine.disease ,digestive system diseases ,stomatognathic diseases ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Cancer research - Abstract
Although the Notch pathway has been reported to be activated in colorectal cancer (CRC), limited information is available regarding the expression and role of its ligand, Jagged 2 (JAG2), in CRC. Using immunohistochemistry, the present study demonstrated that JAG2 protein expression may be detected in up to 95% of CRC cases and is 3-fold upregulated in tumor cells compared to surrounding normal tissues. This finding suggests that JAG2 may have a role in the tumorigenicity of CRC. To further investigate the cellular functions of JAG2 expression in CRC, two different small interfering RNAs (siRNAs) were used to downregulate JAG2 expression in CRC cell lines (HCT116, DLD-1 and HT-29). The results indicated that JAG2 knockdown inhibits the motility and invasiveness of CRC cell lines without significantly affecting cell proliferation. These findings implicate JAG2 in promoting aggressiveness of CRC, and lay the foundation for its future development as a therapeutic target for the treatment of CRC.
- Published
- 2016
- Full Text
- View/download PDF